MX2024013120A - Analisis del transcriptoma para el tratamiento de la inflamacion - Google Patents

Analisis del transcriptoma para el tratamiento de la inflamacion

Info

Publication number
MX2024013120A
MX2024013120A MX2024013120A MX2024013120A MX2024013120A MX 2024013120 A MX2024013120 A MX 2024013120A MX 2024013120 A MX2024013120 A MX 2024013120A MX 2024013120 A MX2024013120 A MX 2024013120A MX 2024013120 A MX2024013120 A MX 2024013120A
Authority
MX
Mexico
Prior art keywords
treating inflammation
transcriptome analysis
disease
dupilumab
treatment
Prior art date
Application number
MX2024013120A
Other languages
English (en)
Spanish (es)
Inventor
Wei Keat Lim
Kaitlyn Gayvert
Sivan Harel
Jennifer Davidson Hamilton
Sara Hamon
Matthew F Wipperman
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024013120A publication Critical patent/MX2024013120A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024013120A 2022-04-26 2024-10-24 Analisis del transcriptoma para el tratamiento de la inflamacion MX2024013120A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263334837P 2022-04-26 2022-04-26
PCT/US2023/066197 WO2023212569A1 (en) 2022-04-26 2023-04-25 Transcriptome analysis for treating inflammation

Publications (1)

Publication Number Publication Date
MX2024013120A true MX2024013120A (es) 2024-12-06

Family

ID=86469406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013120A MX2024013120A (es) 2022-04-26 2024-10-24 Analisis del transcriptoma para el tratamiento de la inflamacion

Country Status (8)

Country Link
US (1) US20230340601A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514995A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515307A (cg-RX-API-DMAC7.html)
CN (1) CN119137282A (cg-RX-API-DMAC7.html)
AU (1) AU2023259352A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246860A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013120A (cg-RX-API-DMAC7.html)
WO (1) WO2023212569A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117949666B (zh) * 2024-01-12 2025-07-15 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用
WO2025244094A1 (ja) * 2024-05-23 2025-11-27 国立研究開発法人理化学研究所 アトピー性皮膚炎患者へのデュピルマブの投与の有効性を予測する方法及びキット
WO2025244092A1 (ja) * 2024-05-23 2025-11-27 国立研究開発法人理化学研究所 アトピー性皮膚炎患者へのデュピルマブの投与の有効性を予測する方法及びキット
WO2026142696A1 (en) * 2024-12-23 2026-07-02 Regeneron Pharmaceuticals, Inc. Transcriptome signature analysis for treating inflammation
CN119932179B (zh) * 2025-04-08 2025-06-27 杭州易文赛生物技术有限公司 用于评价间充质干细胞治疗炎症性肠炎效果的标志物组合物及其应用
CN120510912A (zh) * 2025-05-20 2025-08-19 北京大学人民医院 用于溃疡性结肠炎预测计算机装置及计算机可读存储介质
CN121109581B (zh) * 2025-11-17 2026-03-06 杭州易文赛生物技术有限公司 用于评价间充质干细胞治疗特应性皮炎效果的标志物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック, インコーポレイテッド 好酸球性疾患の診断及び治療方法
JP7431812B2 (ja) * 2018-05-09 2024-02-15 ダームテック,インク. 自己免疫疾患における新規な遺伝子分類とその使用
JP7862322B2 (ja) * 2020-05-22 2026-05-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4r阻害剤の投与により好酸球性食道炎を処置する方法

Also Published As

Publication number Publication date
EP4514995A1 (en) 2025-03-05
CA3246860A1 (en) 2023-11-02
CN119137282A (zh) 2024-12-13
US20230340601A1 (en) 2023-10-26
JP2025515307A (ja) 2025-05-14
AU2023259352A1 (en) 2024-10-10
WO2023212569A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
MX2023007587A (es) Tratamiento de enfermedades hepaticas con inhibidores de efectores b tipo dffa que inducen la muerte celular (cideb).
PH12022550578A1 (en) Method for identifying responders to smarca2/4 degraders
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
MX2019010958A (es) Metodos de tratamiento de tumores.
WO2020154268A3 (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
EA036698B9 (ru) Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
PH12019502710A1 (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
WO2021048619A3 (en) Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
MX2024007806A (es) Metodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos.
WO2019236750A3 (en) Targeted treatment of autism spectrum disorder and other neurological or psychiatric disorders
MX2022002880A (es) Ensayo basado en sangre para diagnosticar y tratar fosforilacion de tau especifica con base en el sitio.
WO2020209988A3 (en) Diverse marker panel for ptsd diagnosis and treatment
MX2015004264A (es) Uso de masitinib para el tratamiento de cancer en subpoblaciones de pacientes identificados mediante factores predictivos.
MX2023006598A (es) Biomarcadores agonistas del trem2 y métodos para usarlos.
ZA202103975B (en) Methods of treating disease with magl inhibitors
CR20230121A (es) Tratamiento de la enfermedad de parkinson
ATE531813T1 (de) System zur überwachung einer bakteriellen tumorbehandlung
WO2019168478A8 (en) A method of determining a risk of cancer
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
MX2018011679A (es) Biomarcadores de proteopatias y usos de los mismos.
EP4327818A3 (en) Improved anti-senescence compounds and uses for the treatment of cancer
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
MX2024007900A (es) Tratamiento de enfermedades renales con inhibidores de la angiopoyetina tipo 3 (angptl3).